Discover
CRMD
CorMedix Inc.
8.47
1 x 8.42
1 x 17.50
bid
ask
+
0.62
7.90%
1 @ 07:43 AM
8.53 +0.06 (0.68%)
| Ytd | -27.17% | |
| 1y | -28.16% |
7.98
day range
8.53
6.13
52 week range
14.96
| Open | 7.99 | Prev Close | 7.85 | Low | 7.98 | High | 8.53 | Mkt Cap | 664.49M |
| Vol | 1.28M | Avg Vol | 1.32M | EPS | 2.17 | P/E | 3.90 | Forward P/E | 17.54 |
| Beta | 1.58 | Short Ratio | 5.12 | Inst. Own | 31.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 8.08 | 200-d Avg | 8.97 | 1yr Est | 16.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-12 | 2025-09 | 0.48 | 0.57 | 0.09 | 18.75% |
| 2025-08-07 | 2025-06 | 0.2 | 0.28 | 0.08 | 40.00% |
| 2025-05-06 | 2025-03 | 0.25 | 0.3 | 0.05 | 20.00% |
| 2025-03-25 | 2024-12 | 0.17 | 0.22 | 0.05 | 29.41% |
| 2024-10-30 | 2024-09 | 0 | N/A | 0.05 | 50.00% |
| 2024-08-14 | 2024-06 | 0 | N/A | 0.01 | 3.85% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-10-31 | Needham | Upgrade | Buy | Buy |
| 2024-08-15 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-08-15 | Needham | Upgrade | Buy | Buy |
| 2024-07-25 | Truist Securities | Upgrade | Buy | Buy |
| 2024-06-19 | Needham | Upgrade | Buy | Buy |
Profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-16 | COSTA PAULO F | Director | 10.00K | Purchase |
| 2024-01-11 | DAVID MATTHEW T M.D. | Chief Financial Officer | 47.93K | Stock Award(Grant) |
| 2023-12-14 | DUNTON ALAN WILLIAM | Director | 15.25K | Purchase |
| 2023-05-17 | KAPLAN MYRON | Director | 196.03K | Purchase |
| 2023-11-15 | LEFKOWITZ STEVEN W | Director | 107.65K | Conversion of Exercise of derivative security |
| 2024-01-11 | MASSON ELIZABETH | Officer | 45.40K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 3.66M | 30.79M | 6.03% |
| 2024-09-29 | Vanguard Group Inc | 3.07M | 25.84M | 5.06% |
| 2024-09-29 | Elliott Investment Management L.p. | 1.55M | 13.06M | 2.56% |
| 2024-09-29 | Rosalind Advisors, Inc. | 1.48M | 12.42M | 2.43% |
| 2024-09-29 | Geode Capital Management, LLC | 1.28M | 10.82M | 2.12% |
| 2024-09-29 | State Street Corporation | 1.23M | 10.32M | 2.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.73M | 14.58M | 2.85% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.40M | 11.82M | 2.31% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 809.91K | 6.82M | 1.33% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 566.54K | 4.77M | 0.93% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 447.45K | 3.77M | 0.74% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 302.40K | 2.55M | 0.50% |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2019-03-26 |